Latest Tax News

Eastern Gas has completed its Venus-2H horizontal appraisal well with 445 metres of interpreted coal contact, but the result now faces a more immediate test: whether the company can fund flow testing with only A$654,000 in cash. Gas deliverability remains unproven, while a proposed A$10 million R&D-backed facility is yet to be finalised.

Australian Bond Exchange generated $1.68 million in positive operating cash flow in Q1 FY27, lifting cash to $1.49 million while repaying $436,000 of borrowings. The result strengthens its balance sheet, though the quarter’s cash inflows included $263,000 in government grants or tax incentives and $150,000 of interest received.

Syntara has reported statistically significant exploratory results for its Parkinson’s-related drug SNT-4728, while advancing blood-cancer and scar studies. The quarter also brought A$4.7 million in R&D funding, but the liquidation of a former buyer threatens a facility relocation and recovery of about A$0.6 million.

Kingsland Minerals ended the September quarter with $752,000 in cash and estimated funding for less than one quarter at current outgoings. Discussions with major shareholder Quinbrook remain non-binding, while the company has paused Leliyn exploration and is considering drilling its gold and uranium projects.

Diatreme Resources has set out a sizeable economic case for its Northern Silica Project, with a pre-tax NPV of $1.29 billion for the base case and $2.419 billion if production expands. The catch is more immediate: the company held $1.9 million in corporate cash at quarter-end, equivalent to about 2.4 quarters of funding at its reported spending rate.

Micro-X has reported a sharp improvement in Rover order activity and more than $3 million in annualised cost savings, while redirecting its strategy towards medical CT. The September quarter still consumed $4.4 million in operating cash, leaving funding dependent on further note proceeds, an expected tax refund and milestone receipts.

H2G says its first PowerSafe stackable sodium-ion battery shipments have sold out, with products now available across Australia’s three eastern states. The company reported a sodium-ion sales pipeline above $4 million, alongside a $10 million-plus supercapacitor pipeline and quarter-end cash of $881,000.

Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.

Aspire Mining has moved the Ovoot Coking Coal Project from planning into site establishment, while its new bond programme has raised US$11.2 million. The funding progress comes alongside only US$2.1 million in quarter-end cash and an estimated 1.8 quarters of available funding.

Power Minerals has reported its strongest Morro do Ferro drilling results yet, alongside a conceptual 9.2 million to 10.7 million tonne Exploration Target in Brazil. But the ASX-listed explorer ended September with A$4.5 million and says it is seeking a strategic capital raising while in a trading halt.

BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.

Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.